A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Compare the Efficacy, Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity Between SB16 (Proposed Denosumab Biosimilar) and Prolia® in Postmenopausal Women With Osteoporosis

SB16-3001

This is a randomised, double-blind, multicentre study to evaluate the efficacy, safety, PK, PD, and immunogenicity of SB16 compared to Prolia® in postmenopausal women with osteoporosis.

2020-11-26

2022-06-20

2022-12-19

Completed

Early phase I

457

Inclusion Criteria: * Postmenopausal women who are 55 to 80 years of age at Screening * Ambulatory and visually unimpaired to participate in the study at Screening, in the opinion of the Investigator * Absolute BMD consistent with T-score at the total hip or lumbar spine of -4 and -2.5 at Screening * At least three evaluable vertebrae within L1 to L4, one evaluable femoral neck, and one evaluable hip joint for BMD measurement at Screening * Biologic naïve at Screening * Body weight of 50 kg and 90 kg at Screening Exclusion Criteria: * One severe or more than two moderate vertebral fractures on spinal X-ray according to Genant classification at Screening * History of hip fracture or bilateral hip replacement at Screening * Uncorrected vitamin D deficiency at Screening * Hypercalcemia or hypocalcaemia at Screening * Inadequate haematological function at Screening * Inadequate renal or hepatic function at Screening * Known allergic reactions, hypersensitivity, or intolerance to denosumab or to any ingredients of the IP, including latex allergy or hereditary problems of fructose intolerance at Screening * May not tolerate long-term calcium or vitamin D supplementation or subject with malabsorption of calcium or vitamin D supplements, in the opinion of the Investigator, at Screening * Use of any of the medications that can affect BMD * Use of any non-biologic IP that is not indicated for osteoporosis from another study or use of an investigational device at Screening * Non-osteoporosis medical conditions that can affect BMD at Screening * Any clinically significant disease or disorder or laboratory abnormality which, in the opinion of the Investigator, would prevent the subject from completing the study or the interpretation of the study results at Screening and Randomisation

{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'RANDOMIZED', 'interventionModel': 'PARALLEL', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}}, 'enrollmentInfo': {'count': 457, 'type': 'ACTUAL'}}

2022-12-20